Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions
NCT03022877 · RWTH Aachen University · NA · withdrawn · last registry update 2022-10-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Rationale obsolete” | – | Registry record, RWTH Aachen University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDE3A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-10-12Phase 3 first posted: Merck Sharp & Dohme LLC, Bomedemstat + Anagrelide (NCT06079879)
- 2023-10-12Results posted on the registry: Baylor College of Medicine, Pentoxifylline (NCT01774487)
- 2023-10-04Also stopped (terminated): Legacy Health System, Trental Pill (NCT03916068)
- 2023-09-26Phase 3 first posted: Sunnybrook Health Sciences Centre, modified PENTOCLO (mPENTOCLO) + sham mPENTOCLO (NCT06055257)
- 2023-09-15Phase 3 first posted: University of Brasilia, Miltefosine 50mg + Pentoxifylline 400mg (NCT06040489)
- 2023-09-14Results posted on the registry: University of Cincinnati, Trental (NCT01508221)
- 2023-08-09Phase 3 first posted: Tenax Therapeutics, Inc., TNX-103 + Placebo (NCT05983250)
- 2023-08-02Phase 3 first posted: Beni-Suef University, tadalafil + Sildenafil (NCT05971667)
- 2023-07-24Results posted on the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Ensifentrine + Placebo (NCT04542057)
- 2023-06-09Phase 3 first posted: Tanta University, Doxycyclin + Pentoxifylline (NCT05897034)
- 2023-05-23Results posted on the registry: Sierra Oncology LLC - a GSK company, Momelotinib + Best Available Therapy (BAT) (NCT02101268)
- 2023-05-03Phase 3 first posted: Menoufia University, Inhaled Milrinone + IV Milrinone (NCT05838846)
- 2023-04-03Results posted on the registry: M.D. Anderson Cancer Center, Atorvastatin + Pentoxifylline (NCT03830164)
- 2023-03-14Phase 3 first posted: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, levosimendan + 5% glucose injection (NCT05768230)
- 2023-03-09Results posted on the registry: Orion Corporation, Orion Pharma, Levosimendan (NCT03948178)
- 2023-03-09Also stopped (terminated): Orion Corporation, Orion Pharma, Levosimendan (NCT03948178)
- 2023-02-24Phase 3 first posted: Nuance Pharma (shanghai) Co., Ltd, Ensifentrine + Placebo (NCT05743075)
- 2023-02-02Also stopped (withdrawn): Rush University Medical Center, amifostine trihydrate + cytarabine (NCT00003407)
- 2023-01-18Also stopped (withdrawn): Sadat City University, Pentoxifylline + Placebo (NCT04433988)
- 2022-10-03Results posted on the registry: Processa Pharmaceuticals, PCS499 (NCT03698864)
- 2022-09-22Results posted on the registry: Verona Pharma Inc, Ensifentrine Dose 1 + Placebo pMDI (NCT04527471)
- 2022-08-24Phase 3 first posted: University Health Network, Toronto, Ibudilast + Pentoxifylline (NCT05513560)
- 2022-08-04Phase 3 first posted: Tanta University, Tadalafil 20Mg Oral Tablet + Pentoxifylline 400 MG Oral Tablet (NCT05487755)
- 2022-08-01Also stopped (withdrawn): Henry Ford Health System, Placebo + Pentoxifylline (NCT01337349)
- 2022-07-25Results posted on the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Part A: RPL554 + Placebos (NCT04091360)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision